UNSPSC 51391807: Hydroxyamphetamine hydrobromide

This classification denotes an adrenergic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59IG47SZ0E. European Medicines Agency schedules Hydroxyamfetamine hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02581MIG. Hydroxyamphetamine hydrobromide generally arises in the molecular formula C9H13NO.BRH. The term 'hydroxyamphetamine hydrobromide' is a U.S. Pharmacopeial Convention designation.

As of Q4 2014, HYDROXYAMPHETAMINE HYDROBROMIDE remains the US FDA Preferred Term for this commodity. Hydroxyamphetamine hydrobromide bears US NLM identifiers UMLS ID C0282278 and NCI Concept Code C47558. SMILES: OC1CCC(CC(N)C)CC1.

UNSPSC 51391807 Hydroxyamphetamine hydrobromide is a Commodity code nominally identifying a specific pharmaceutical product, but recent state and local opportunities posted under this code show little activity directly aligned with the chemical itself. The single concrete procurement opportunity on record — Seminole County, Florida's IFB for naloxone and drug deactivation systems — involves a different active pharmaceutical ingredient than hydroxyamphetamine and falls outside the code's nominal scope. The Texas Health and Human Services Commission's Request for Information on direct-to-manufacturer prescription programs is similarly misaligned with the code, focusing on pharmacy benefit program design rather than procurement of hydroxyamphetamine hydrobromide specifically. State and local buyers using this code appear to be primarily county health departments and state health agencies, but the recent opportunities do not support active procurement demand for the named commodity.

No recent state and local solicitations for hydroxyamphetamine hydrobromide itself are present in the available record. The Seminole County opportunity (IFB 60459723LAS, due July 26, 2023) and the Texas HHS Commission RFI (HHS0017013, posted April 3, 2026) represent the only tagged opportunities and both concern different pharmaceutical products and program models. Geographic activity, to the extent the misaligned opportunities indicate it, centers on Florida and Texas, but neither opportunity supports demand signals for this specific commodity. Absent relevant recent procurement activity under this code, the watch list for hydroxyamphetamine hydrobromide at the state and local level appears limited; firms pursuing this market segment should monitor county and state pharmacy procurement channels directly rather than relying on UNSPSC-coded opportunity flow.